We offer a complete range of diagnostic and treatment services for patients with thoracic malignancies, including:
Members of the Thoracic Oncology program have taken leading roles in the development of new drugs and drug combinations for the treatment of thoracic malignancies. Our center offers access to some of the most important new drugs in development for the treatment of lung cancer and other thoracic cancers. These trials test a variety of approaches, including the evaluation of new drugs for lung cancer as well as potentially better ways of using old drugs. These new drugs contain different mechanisms of action than previously used anti-cancer drugs. UMGCC has pioneered a number of treatments for locally advanced and advanced lung cancer. Other clinical trials in lung cancer include new drugs for initial therapy as well as second and subsequent therapies.
The University of Maryland is a founding member of the Cancer and Leukemia Group B (CALGB), one of the major NCI funded national cancer research organizations. Members of the Thoracic Oncology Program are leading national studies of new therapeutics and approaches through CALGB. Members of the program have also been leaders in research to minimize the side effects of therapy as well as
Members of our staff have pioneered minimally invasive surgical techniques, including thoracoscopic surgical staging. This new procedure is a more accurate method of defining the spread and extent of cancer of the lung and the esophagus, the fastest growing category of cancer in the United States. Using this minimally invasive surgical method, physicians can more effectively tailor treatment to the needs of the individual patient, helping to select which patients will benefit the most from aggressive therapy and improving outcomes.
The Radiation Oncology Department offers the most modern equipment as well as the most experienced treatment planning. New approaches to radiation therapy including Gamma Knife treatment of brain metastases, 3-dimensional treatment planning, and intensity modulated radiotherapy (IMRT) were pioneered at the University of Maryland. We were the first academic medical program in the region to offer the fully-integrated Trilogy™ System linear accelerator, which combines the most advanced imaging and treatment technologies and can be used to deliver the widest range of external beam radiotherapies available.
The University is also a full member of the Radiation Therapy Oncology Group (RTOG). Members of the program are prominent in RTOG as national investigators of new approaches integrating radiation in the management of thoracic malignancies.
If you have a patient who would benefit from the expertise and treatment we offer, call the Thoracic Oncology Nurse Coordinator to schedule and appointment: (410) 328-6366 or 1-800-888-8823.
Patients with metastatic disease should call (410) 328-7904 or 1-800-888-8823.